Otsuka moved to acquire Transcend Therapeutics in a deal valued at about $1.2 billion, including a $700 million upfront payment and potential additional milestones. The transaction would bring Transcend’s TSND-201, a methylone analog aimed at rapidly restoring neuroplasticity, into Otsuka’s psychiatry pipeline. The acquisition is positioned around a post-traumatic stress disorder strategy: TSND-201’s mid-stage results were published in JAMA Psychiatry, and recruitment is underway for a Phase 3 U.S. trial. Otsuka expects to complete the deal between April and June, pending customary closing conditions. The package signals renewed large-pharma confidence in neuroplasticity-focused psychiatric development and reinforces the broader race among sponsors to secure late-stage assets with potential fast-acting differentiation.